Evaluating the safety, feasibility, and outcomes of the Senhance robotic system in robot-assisted radical prostatectomy: a systematic review and single-arm meta-analysis.

With the continuous advancement of robotic-assisted surgical platforms, evaluating the safety and feasibility of emerging systems is essential. This study aims to systematically assess the Senhance robotic system in performing radical prostatectomy for prostate cancer. This investigation employed a systematic review paired with a single-arm meta-analysis, conducted in line with PRISMA standards and with the study protocol pre-registered in the PROSPERO database (CRD42025636976). We queried major databases-including PubMed, Web of Science, Embase, and the Cochrane Library-for articles published until December 2024 that focused on the utilization of the Senhance robotic system in radical prostatectomy. Relevant data were extracted on key surgical parameters (e.g., duration of the procedure, intraoperative blood loss, length of hospital stay, and catheter removal time), as well as on postoperative pain levels and oncological outcomes (including positive surgical margin rates, biochemical recurrence, and urinary incontinence), in addition to overall complication rates. All analyses were performed using Stata 18 SE; heterogeneity among studies was quantified using the I statistic, and the stability of the results was assessed through a leave-one-out sensitivity analysis. Five studies encompassing a total of 567 patients were included. The pooled estimates demonstrated a mean operative time of 200.05 min (95% CI 188.44-211.67) and a mean intraoperative blood loss of 257.02 mL (95% CI 216.18-297.86). The mean hospital stay and catheter removal time were 6.20 days (95% CI 4.70-7.70) and 11.07 days (95% CI 9.26-12.89), respectively. Oncological and functional outcomes revealed a positive surgical margin rate of 30% (95% CI 26-33%), a urinary incontinence rate of 14% (95% CI 4-23%), and a biochemical recurrence rate of 5% (95% CI 1-8%). Postoperative pain, measured by VAS scores, improved from 3.11 on day 1 to 0.38 at discharge. Despite significant heterogeneity in several outcomes, sensitivity analyses confirmed the stability of these findings. Our findings indicate that the Senhance robotic platform is a promising tool for radical prostatectomy, delivering oncological and functional outcomes that align with established surgical methods while also offering potential cost benefits. These results support its feasibility as an alternative to traditional systems. However, to solidify its role in urological practice, further research-especially well-designed randomized controlled trials-is necessary to confirm these initial observations and optimize its clinical application.